Public biopharmaceutical companies have had few problems raising significant cash in 2018, but Proteostasis Therapeutics Inc. withdrew a planned offering of 9m shares on March 20 after an investor with a short position in Proteostasis stock launched an attack on the company's credibility.
Cambridge, Mass.-based Proteostasis announced its proposed offering on March 19 when its stock closed at $6.99 per share, which was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?